drugset
drugset / Trial / NCT07007806

Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir

NCT07007806 ↗

Phase 1 Completed 20 enrolled Atea Pharmaceuticals, Inc.
NaSequentialOpen-labelTreatment

Summary

Drug-drug interaction study between Omeprazole and Bemnifosbuvir/Ruzasvir (BEM/RZR)

Timeline

Start
2025-05-09
Primary completion
2025-06-28
Completion
2025-06-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Bemnifosbuvir/Ruzasvir Unknown 180 mg —
Subject Bemnifosbuvir/Ruzasvir Unknown 550 mg —
Subject Omeprazole Other / unclassified 20 mg —
Subject Omeprazole Other / unclassified 40 mg —

Indications

No indication recorded.